Tumor-Residing Batf3 Dendritic Cells Are Required for Effector T Cell Trafficking and Adoptive T Cell Therapy

Cancer Cell

Volumn 31, Issue 5, 2017, Pages 711-723.e4

  Spranger, Stefani ^a   Dai, Daisy ^a   Horton, Brendan ^a   Gajewski, Thomas F ^a,b  

^a UNIVERSITY OF CHICAGO   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

Author keywords

adoptive T cell transfer; immune escape; immunotherapy resistance; non T cell inflamed tumor microenvironment; T cell inflamed tumor microenvironment

Indexed keywords

ALPHA E INTEGRINS; ALPHA INTEGRIN; BASIC LEUCINE ZIPPER TRANSCRIPTION FACTOR; BETA CATENIN; CTNNB1 PROTEIN, MOUSE; CXCL10 PROTEIN, MOUSE; CXCL9 CHEMOKINE; CXCL9 PROTEIN, MOUSE; GAMMA INTERFERON INDUCIBLE PROTEIN 10; LEUKOCYTE ANTIGEN; REPRESSOR PROTEIN; SNFT PROTEIN, HUMAN; SNFT PROTEIN, MOUSE;

ADOPTIVE IMMUNOTHERAPY; ANIMAL; CD8+ T LYMPHOCYTE; CELL PROLIFERATION; DEFICIENCY; DENDRITIC CELL; GENETICS; GENOTYPE; IMMUNOLOGICAL MEMORY; IMMUNOLOGY; KNOCKOUT MOUSE; MELANOMA; METABOLISM; NEUTROPHIL CHEMOTAXIS; PATHOLOGY; PHENOTYPE; PROCEDURES; SIGNAL TRANSDUCTION; SKIN NEOPLASMS; T LYMPHOCYTE; TIME FACTOR; TRANSPLANTATION; TUMOR CELL LINE; TUMOR ESCAPE; TUMOR MICROENVIRONMENT; TUMOR VOLUME;

ANIMALS; ANTIGENS, CD; BASIC-LEUCINE ZIPPER TRANSCRIPTION FACTORS; BETA CATENIN; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; CELL PROLIFERATION; CHEMOKINE CXCL10; CHEMOKINE CXCL9; CHEMOTAXIS, LEUKOCYTE; DENDRITIC CELLS; GENOTYPE; IMMUNOLOGIC MEMORY; IMMUNOTHERAPY, ADOPTIVE; INTEGRIN ALPHA CHAINS; MELANOMA; MICE, KNOCKOUT; PHENOTYPE; REPRESSOR PROTEINS; SIGNAL TRANSDUCTION; SKIN NEOPLASMS; T-LYMPHOCYTES; TIME FACTORS; TUMOR BURDEN; TUMOR ESCAPE; TUMOR MICROENVIRONMENT;

EID: 85019144614     PISSN: 15356108     EISSN: 18783686     Source Type: Journal    
DOI: 10.1016/j.ccell.2017.04.003     Document Type: Article

References (48)

1. Alexandre, Y.O., Ghilas, S., Sanchez, C., Le Bon, A., Crozat, K., Dalod, M., XCR1+ dendritic cells promote memory CD8+ T cell recall upon secondary infections with Listeria monocytogenes or certain viruses. J. Exp. Med. 213 (2016), 75–92.
2. Bosenberg, M., Muthusamy, V., Curley, D.P., Wang, Z., Hobbs, C., Nelson, B., Nogueira, C., Horner, J.W. 2nd, Depinho, R., Chin, L., Characterization of melanocyte-specific inducible Cre recombinase transgenic mice. Genesis 44 (2006), 262–267.
3. Bottcher, J.P., Beyer, M., Meissner, F., Abdullah, Z., Sander, J., Hochst, B., Eickhoff, S., Rieckmann, J.C., Russo, C., Bauer, T., et al. Functional classification of memory CD8(+) T cells by CX3CR1 expression. Nat. Commun., 6, 2015, 8306.
4. Brahmer, J.R., Tykodi, S.S., Chow, L.Q., Hwu, W.J., Topalian, S.L., Hwu, P., Drake, C.G., Camacho, L.H., Kauh, J., Odunsi, K., et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N. Engl. J. Med. 366 (2012), 2455–2465.
5. Broz, M.L., Binnewies, M., Boldajipour, B., Nelson, A.E., Pollack, J.L., Erle, D.J., Barczak, A., Rosenblum, M.D., Daud, A., Barber, D.L., et al. Dissecting the tumor myeloid compartment reveals rare activating antigen-presenting cells critical for T cell immunity. Cancer Cell 26 (2014), 638–652.
6. Cyster, J.G., Goodnow, C.C., Pertussis toxin inhibits migration of B and T lymphocytes into splenic white pulp cords. J. Exp. Med. 182 (1995), 581–586.
7. Dankort, D., Curley, D.P., Cartlidge, R.A., Nelson, B., Karnezis, A.N., Damsky, W.E. Jr., You, M.J., DePinho, R.A., McMahon, M., Bosenberg, M., Braf(V600E) cooperates with Pten loss to induce metastatic melanoma. Nat. Genet. 41 (2009), 544–552.
8. Dudley, M.E., Wunderlich, J.R., Robbins, P.F., Yang, J.C., Hwu, P., Schwartzentruber, D.J., Topalian, S.L., Sherry, R., Restifo, N.P., Hubicki, A.M., et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 298 (2002), 850–854.
9. Dufour, J.H., Dziejman, M., Liu, M.T., Leung, J.H., Lane, T.E., Luster, A.D., IFN-gamma-inducible protein 10 (IP-10; CXCL10)-deficient mice reveal a role for IP-10 in effector T cell generation and trafficking. J. Immunol. 168 (2002), 3195–3204.
10. DuPage, M., Cheung, A.F., Mazumdar, C., Winslow, M.M., Bronson, R., Schmidt, L.M., Crowley, D., Chen, J., Jacks, T., Endogenous T cell responses to antigens expressed in lung adenocarcinomas delay malignant tumor progression. Cancer Cell 19 (2011), 72–85.
11. DuPage, M., Mazumdar, C., Schmidt, L.M., Cheung, A.F., Jacks, T., Expression of tumour-specific antigens underlies cancer immunoediting. Nature 482 (2012), 405–409.
12. Edelson, B.T., Kc, W., Juang, R., Kohyama, M., Benoit, L.A., Klekotka, P.A., Moon, C., Albring, J.C., Ise, W., Michael, D.G., et al. Peripheral CD103+ dendritic cells form a unified subset developmentally related to CD8alpha+ conventional dendritic cells. J. Exp. Med. 207 (2010), 823–836.
13. Engelhardt, J.J., Boldajipour, B., Beemiller, P., Pandurangi, P., Sorensen, C., Werb, Z., Egeblad, M., Krummel, M.F., Marginating dendritic cells of the tumor microenvironment cross-present tumor antigens and stably engage tumor-specific T cells. Cancer Cell 21 (2012), 402–417.
14. Fuertes, M.B., Kacha, A.K., Kline, J., Woo, S.R., Kranz, D.M., Murphy, K.M., Gajewski, T.F., Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8{alpha}+ dendritic cells. J. Exp. Med. 208 (2011), 2005–2016.
15. Fuertes, M.B., Woo, S.R., Burnett, B., Fu, Y.X., Gajewski, T.F., Type I interferon response and innate immune sensing of cancer. Trends Immunol. 34 (2013), 67–73.
16. Gounari, F., Signoretti, S., Bronson, R., Klein, L., Sellers, W.R., Kum, J., Siermann, A., Taketo, M.M., von Boehmer, H., Khazaie, K., Stabilization of beta-catenin induces lesions reminiscent of prostatic intraepithelial neoplasia, but terminal squamous transdifferentiation of other secretory epithelia. Oncogene 21 (2002), 4099–4107.
17. Groom, J.R., Luster, A.D., CXCR3 in T cell function. Exp. Cell Res. 317 (2011), 620–631.
18. Halle, S., Keyser, K.A., Stahl, F.R., Busche, A., Marquardt, A., Zheng, X., Galla, M., Heissmeyer, V., Heller, K., Boelter, J., et al. In vivo killing capacity of cytotoxic T cells is limited and involves dynamic interactions and T cell cooperativity. Immunity 44 (2016), 233–245.
19. Harlin, H., Meng, Y., Peterson, A.C., Zha, Y., Tretiakova, M., Slingluff, C., McKee, M., Gajewski, T.F., Chemokine expression in melanoma metastases associated with CD8+ T-cell recruitment. Cancer Res. 69 (2009), 3077–3085.
20. Hodi, F.S., O'Day, S.J., McDermott, D.F., Weber, R.W., Sosman, J.A., Haanen, J.B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J.C., et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363 (2010), 711–723.
21. Hugo, W., Zaretsky, J.M., Sun, L., Song, C., Moreno, B.H., Hu-Lieskovan, S., Berent-Maoz, B., Pang, J., Chmielowski, B., Cherry, G., et al. Genomic and transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma. Cell 165 (2016), 35–44.
22. Ishikawa, H., Barber, G.N., STING is an endoplasmic reticulum adaptor that facilitates innate immune signalling. Nature 455 (2008), 674–678.
23. Joshi, N.S., Akama-Garren, E.H., Lu, Y., Lee, D.Y., Chang, G.P., Li, A., DuPage, M., Tammela, T., Kerper, N.R., Farago, A.F., et al. Regulatory T cells in tumor-associated tertiary lymphoid structures suppress anti-tumor T cell responses. Immunity 43 (2015), 579–590.
24. Klebanoff, C.A., Gattinoni, L., Restifo, N.P., CD8+ T-cell memory in tumor immunology and immunotherapy. Immunol. Rev. 211 (2006), 214–224.
25. Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J.J., Cowey, C.L., Lao, C.D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N. Engl. J. Med. 373 (2015), 23–34.
26. Manning, T.C., Rund, L.A., Gruber, M.M., Fallarino, F., Gajewski, T.F., Kranz, D.M., Antigen recognition and allogeneic tumor rejection in CD8+ TCR transgenic/RAG(-/-) mice. J. Immunol. 159 (1997), 4665–4675.
27. Matsushita, H., Vesely, M.D., Koboldt, D.C., Rickert, C.G., Uppaluri, R., Magrini, V.J., Arthur, C.D., White, J.M., Chen, Y.S., Shea, L.K., et al. Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting. Nature 482 (2012), 400–404.
28. Meijering, E., Dzyubachyk, O., Smal, I., Methods for cell and particle tracking. Methods Enzymol. 504 (2012), 183–200.
29. Mempel, T.R., Henrickson, S.E., Von Andrian, U.H., T-cell priming by dendritic cells in lymph nodes occurs in three distinct phases. Nature 427 (2004), 154–159.
30. Mikucki, M.E., Fisher, D.T., Matsuzaki, J., Skitzki, J.J., Gaulin, N.B., Muhitch, J.B., Ku, A.W., Frelinger, J.G., Odunsi, K., Gajewski, T.F., et al. Non-redundant requirement for CXCR3 signalling during tumoricidal T-cell trafficking across tumour vascular checkpoints. Nat. Commun., 6, 2015, 7458.
31. Morgan, R.A., Dudley, M.E., Wunderlich, J.R., Hughes, M.S., Yang, J.C., Sherry, R.M., Royal, R.E., Topalian, S.L., Kammula, U.S., Restifo, N.P., et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 314 (2006), 126–129.
32. Nishimura, T., Nakui, M., Sato, M., Iwakabe, K., Kitamura, H., Sekimoto, M., Ohta, A., Koda, T., Nishimura, S., The critical role of Th1-dominant immunity in tumor immunology. Cancer Chemother. Pharmacol. 46:Suppl (2000), S52–S61.
33. Padovan, E., Spagnoli, G.C., Ferrantini, M., Heberer, M., IFN-alpha2a induces IP-10/CXCL10 and MIG/CXCL9 production in monocyte-derived dendritic cells and enhances their capacity to attract and stimulate CD8+ effector T cells. J. Leukoc. Biol. 71 (2002), 669–676.
34. Peng, W., Chen, J.Q., Liu, C., Malu, S., Creasy, C., Tetzlaff, M.T., Xu, C., McKenzie, J.A., Zhang, C., Liang, X., et al. Loss of PTEN promotes resistance to T cell-mediated immunotherapy. Cancer Discov. 6 (2015), 202–216.
35. Roberts, E.W., Broz, M.L., Binnewies, M., Headley, M.B., Nelson, A.E., Wolf, D.M., Kaisho, T., Bogunovic, D., Bhardwaj, N., Krummel, M.F., Critical role for CD103+/CD141+ dendritic cells bearing CCR7 for tumor antigen trafficking and priming of T cell immunity in melanoma. Cancer Cell 30 (2016), 324–336.
36. Rosenberg, S.A., Restifo, N.P., Adoptive cell transfer as personalized immunotherapy for human cancer. Science 348 (2015), 62–68.
37. Salerno, E.P., Olson, W.C., McSkimming, C., Shea, S., Slingluff, C.L. Jr., T cells in the human metastatic melanoma microenvironment express site-specific homing receptors and retention integrins. Int. J. Cancer 134 (2014), 563–574.
38. Salmon, H., Idoyaga, J., Rahman, A., Leboeuf, M., Remark, R., Jordan, S., Casanova-Acebes, M., Khudoynazarova, M., Agudo, J., Tung, N., et al. Expansion and activation of CD103(+) dendritic cell progenitors at the tumor site enhances tumor responses to therapeutic PD-L1 and BRAF inhibition. Immunity 44 (2016), 924–938.
39. Schietinger, A., Arina, A., Liu, R.B., Wells, S., Huang, J., Engels, B., Bindokas, V., Bartkowiak, T., Lee, D., Herrmann, A., et al. Longitudinal confocal microscopy imaging of solid tumor destruction following adoptive T cell transfer. Oncoimmunology, 2, 2013, e26677.
40. Schmittgen, T.D., Livak, K.J., Analyzing real-time PCR data by the comparative C(T) method. Nat. Protoc. 3 (2008), 1101–1108.
41. Sirma Ekmekci, S., G Ekmekci, C., Kandilci, A., Gulec, C., Akbiyik, M., Emrence, Z., Abaci, N., Karakas, Z., Agaoglu, L., et al. SET oncogene is upregulated in pediatric acute lymphoblastic leukemia. Tumori 98 (2012), 252–256.
42. Spiotto, M.T., Yu, P., Rowley, D.A., Nishimura, M.I., Meredith, S.C., Gajewski, T.F., Fu, Y.X., Schreiber, H., Increasing tumor antigen expression overcomes “ignorance” to solid tumors via crosspresentation by bone marrow-derived stromal cells. Immunity 17 (2002), 737–747.
43. Spranger, S., Koblish, H.K., Horton, B., Scherle, P.A., Newton, R., Gajewski, T.F., Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8(+) T cells directly within the tumor microenvironment. J. Immunother. Cancer, 2, 2014, 3.
44. Spranger, S., Bao, R., Gajewski, T.F., Melanoma-intrinsic beta-catenin signalling prevents anti-tumour immunity. Nature 523 (2015), 231–235.
45. Topalian, S.L., Taube, J.M., Anders, R.A., Pardoll, D.M., Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy. Nat. Rev. Cancer 16 (2016), 275–287.
46. Tumeh, P.C., Harview, C.L., Yearley, J.H., Shintaku, I.P., Taylor, E.J., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 515 (2014), 568–571.
47. Woo, S.R., Fuertes, M.B., Corrales, L., Spranger, S., Furdyna, M.J., Leung, M.Y., Duggan, R., Wang, Y., Barber, G.N., Fitzgerald, K.A., et al. STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors. Immunity 41 (2014), 830–842.
48. Yu, P., Lee, Y., Liu, W., Krausz, T., Chong, A., Schreiber, H., Fu, Y.X., Intratumor depletion of CD4+ cells unmasks tumor immunogenicity leading to the rejection of late-stage tumors. J. Exp. Med. 201 (2005), 779–791.